EUVIMEDEUVIMED entdecken
Open Access

The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines

Evelyn J Franco, Jaime L Rodriquez, Justin J Pomeroy, Kaley C Hanrahan, Ashley N Brown iD

Antiviral Chemistry and Chemotherapy · 2018-01 · 26

DOI: 10.1177/2040206618807580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antiviral Chemistry and Chemotherapy, online erschienen am 24.10.2018. Verfasst von Evelyn J Franco und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Institute for Therapeutic Innovation, University of Florida College of Medicine, Orlando, FL, USA. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chikungunya virus (CHIKV) is a mosquito-borne virus that has recently emerged in the Western Hemisphere. Approved antiviral therapies or vaccines for the treatment or prevention of CHIKV infections are not available. This study aims to evaluate the antiviral activity of commercially available broad-spectrum antivirals against CHIKV. Due to host cell-specific variability in uptake and intracellular processing of drug, we evaluated the antiviral effects of each agent in three cell lines. Antiviral activities of ribavirin (RBV), interferon-alfa (IFN-α) and favipiravir (FAV) were assessed in CHIKV-infected Vero, HUH-7, and A549 cells. CHIKV-infected cells were treated with increasing concentrations of each agent for three days and viral burden was quantified by plaque assay on Vero cells. Cytotoxic effects of RBV, FAV and IFN-α were also evaluated. Antiviral activity differed depending on the cell line used for evaluation. RBV had the greatest antiviral effect in HUH-7 cells (EC 50 = 2.575 µg/mL); IFN-α was most effective in A549 cells (EC 50 = 4.235 IU/mL); and FAV in HUH-7 cells (EC 50 = 20.00 μg/mL). The results of our study show FAV and IFN-α are the most promising candidates, as their use led to substantial reductions in viral burden at clinically achievable concentrations in two human-derived cell lines. FAV is an especially attractive candidate for further investigation due to its oral bioavailability. These findings also highlight the importance of cell line selection for preclinical drug trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

A549 CellsAmidesAnimalsAntiviral AgentsCell Line, TumorChikungunya FeverChikungunya virusChlorocebus aethiopsDose-Response Relationship, DrugHumansInterferon-alphaMicrobial Sensitivity TestsMolecular StructurePyrazinesRibavirinStructure-Activity RelationshipVero Cells

Stichwörter der Autor:innen

Chikungunya virusantiviral agentsdrug repurposingfavipiravirinterferon-alpharibavirin

Substanzen

AmidesAntiviral AgentsInterferon-alphaPyrazinesRibavirinfavipiravir

Autor:innen und Institutionen

  • Department of Medicine, Institute for Therapeutic Innovation, University of Florida College of Medicine, Orlando, FL, USA.
  • Department of Pharmaceutics, University of Florida College of Pharmacy, Orlando, FL, USA.

ORCID-Profile: Ashley N Brown

Zitieren

APA

Franco, E. J., Rodriquez, J. L., Pomeroy, J. J., Hanrahan, K. C., & Brown, A. N. (2018). The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines. Antiviral Chemistry and Chemotherapy, 26. https://doi.org/10.1177/2040206618807580

Vancouver

Franco EJ, Rodriquez JL, Pomeroy JJ, Hanrahan KC, Brown AN. The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines. Antiviral Chemistry and Chemotherapy. 2018;26. doi:10.1177/2040206618807580

BibTeX
@article{Franco2018,
  author = {Franco, Evelyn J and Rodriquez, Jaime L and Pomeroy, Justin J and Hanrahan, Kaley C and Brown, Ashley N},
  title = {The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines},
  journal = {Antiviral Chemistry and Chemotherapy},
  year = {2018},
  volume = {26},
  doi = {10.1177/2040206618807580}
}
Kostenlos starten →